Actively Recruiting
Stem Cell Applications in Biliary Atresia Patients
Led by Necmi Kadıoğlu Hospital · Updated on 2024-09-19
64
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success in treating children with biliary atresia (BA). This study aims to evaluate the efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy in BA through a multicentric randomized controlled trial.
CONDITIONS
Official Title
Stem Cell Applications in Biliary Atresia Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants diagnosed with liver cirrhosis due to biliary atresia after Kasai's operation
- Patients aged 2 months or older
- Signs of cirrhosis after surgery, including enlarged liver, congestive enlarged spleen, elevated liver enzymes, esophageal varices confirmed by endoscopy, and cirrhosis confirmed by liver biopsy
You will not qualify if you...
- Epilepsy
- Neurological disorders
- Coagulation disorders
- Diabetes
- Syndromic type biliary atresia
- Allergies to anesthetic agents
- Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys
- Active infections
- Severe psychiatric disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Esenyurt State Hospital
Istanbul, Istanbul, Turkey (Türkiye), 34340
Actively Recruiting
Research Team
M
Mustafa Azizoglu, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here